• Neoadjuvant therapy in resectable/borderline resectable pancreatic cancer
• Best neoadjuvant strategy
• 1st line and subsequent therapies in pancreatic cancer: Doublet vs Triplets
• biomarkers for metastatic patients

Moderator: Dr. Abdullah Alsharm

Panel:

• Role of laparoscopy assessment before perioperative therapy?
• What to do in patients with poor response to neoadjuvant therapy?
• Role of biomarkers e.g MSI in decision-making before perioperative therapy?
• Patients with limited peritoneal metastasis: Role of HIPEC?
• Role of immunetherapy with perioperative therapy non-metastatic gastric cancer?

Moderator:  Dr. Fahad Ibnshamsah